Navigation Links
Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress

SOMERSET, N.J., Aug. 22 /PRNewswire-FirstCall/ - Alfacell Corporation (Nasdaq: ACEL) today announced that a paper published in the International Journal of Oncology (2007; Vol. 31, Issue 3: 663-669) reports that ONCONASE(R) substantially decreases reactive oxygen intermediates (ROI) in normal cell types and tumor cell lines. The observed antioxidant activity of ONCONASE may be important to its cytotoxic effect on cancer cells and mechanistic synergism with other anti-cancer agents.

The pre-clinical in vitro research conducted by Alfacell and researchers at New York Medical College demonstrated that treatment of cells in cultures with ONCONASE reduced intracellular oxidative stress by suppressing ROI generation and promoting their degradation. The anti-oxidative function of ONCONASE may be an important element of its antiproliferative/cytotoxic activity towards cancer cells and a possible mechanism of its well-documented synergism with other anti-cancer agents. Additionally, the data indicate that ONCONASE has a propensity to reverse the generation of ROI from asbestos exposure in mesothelial cells. The Company is currently conducting a Phase IIIb human clinical trial of ONCONASE for the treatment of patients suffering from unresectable malignant mesothelioma.

"The data further confirm the cytotoxic effect of ONCONASE on cancer cells," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "ONCONASE's therapeutic potential is broad. This study shows that ONCONASE has potential not only for cancer, but for conditions pathogenetically related to oxidative stress or the activation of NF-kappa B, such as inflammation, autoimmune diseases, atherosclerosis and septic shock."


ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:

David Schull or Wendy Lau Andreas Marathovouniotis

Russo Partners Russo Partners

212-845-4271 212-845-4253

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/25/2015)... , Nov. 25, 2015  The American Academy ... Gynecologists (ACOG), and the March of Dimes cheered ... Protecting Our Infants Act of 2015 (S.799), ... of newborns born exposed to drugs, such as ... bill,s introduction, all three organizations have worked together ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... a new product dealer. Joining more than 30 HealthPostures’ dealers located throughout the ... space and increase the number of corporate, industrial, manufacturing and government workers and ...
(Date:11/30/2015)... ... 30, 2015 , ... Bayco Products, Inc today announced the introduction of three Nightstick® brand LED ... of three different colors; red ( NSP-1632 ), yellow ( NSP-1634 ) and blue ( ... in constant-on mode, or 27 hours in blinking strobe mode using a fresh set of ...
(Date:11/29/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Women's Excellence is once again accredited by the American Institute of ... review process that allows practices to demonstrate that they meet or exceed ...
(Date:11/29/2015)... ... 29, 2015 , ... NewsWatch featured X-wing as part of its monthly Tech ... a technology expert and special reporter for NewsWatch, conducted the review and shared with ... It’s the future because flying cars are about to become a reality. Where’s the ...
(Date:11/29/2015)... ... 29, 2015 , ... Doctors who missed a case of mesothelioma in a ... mesothelioma and push for a diagnosis, especially in people exposed to asbestos. Surviving Mesothelioma ... read it now. , Researchers at Gifu Prefectural Tajimi Hospital in Japan ...
Breaking Medicine News(10 mins):